Search results
Mar 16, 2021 · TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ -- Chemomab Ltd ., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related...
Mar 15, 2021 · Anchiano Therapeutics. Mon, Mar 15, 2021, 5:54 PM 5 min read. Anchiano shareholders approve all resolutions at shareholder meeting. The merged company is expected to receive approximate gross...
- Anchiano Therapeutics
Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions that involve inflammation and fibrosis and have high unmet need. Our Vision. Innovation. Translating novel biological insights into transformative treatments. Evidence Driven.
Neil Cohen served as interim CEO of Anchiano Therapeutics (NASDAQ: ANCN) from October 2020 until its merger with Chemomab in March 2021. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until ...
Dec 15, 2020 · CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd....
Anchiano Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer. Website....
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity.
